Eli Lilly | LLY - Debt

Stock Price
989.12
Daily Change
4.04 0.41%
Monthly
-4.53%
Yearly
19.93%
Q1 Forecast
955.33

Eli Lilly reported $42.51B in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Abbott USD 12.94B 496M Sep/2025
ALKERMES USD 71.6M 1.08M Sep/2025
Amgen USD 54.59B 1.62B Sep/2025
AstraZeneca USD 32.63B 207M Sep/2025
Baxter International USD 9.71B 13M Sep/2025
Biogen USD 6.29B 1.7M Dec/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Drreddys Laboratories INR 67.73B 19.09B Dec/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Gilead Sciences USD 24.94B 5M Sep/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Glaxosmithkline GBP 17.75B 396M Sep/2025
J&J USD 45.8B 4.97B Sep/2025
Medtronic USD 29.1B 491M Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
Novartis USD 32.64B 1.37B Jun/2025
Novartis USD 32.02B 615M Sep/2025
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Perrigo USD 3.64B 7.2M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
Phibro Animal Health USD 474.17M 730K Sep/2024
Prestige Brands USD 1.04B 1.7M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 21.76B 530M Sep/2025
Sanofi EUR 21.76B 530M Sep/2025
United Therapeutics USD 200M 100M Mar/2025
Zoetis USD 7.27B 482M Sep/2025